WO2017141204A3 - Biopolymères greffés/modifiés au biguanide en tant que véhicules d'administration de médicament - Google Patents
Biopolymères greffés/modifiés au biguanide en tant que véhicules d'administration de médicament Download PDFInfo
- Publication number
- WO2017141204A3 WO2017141204A3 PCT/IB2017/050909 IB2017050909W WO2017141204A3 WO 2017141204 A3 WO2017141204 A3 WO 2017141204A3 IB 2017050909 W IB2017050909 W IB 2017050909W WO 2017141204 A3 WO2017141204 A3 WO 2017141204A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- entry
- promoting
- agent
- relates
- polypeptides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne des composés et des procédés ayant des propriétés de promotion d'entrée (généralement désignées d'administration de médicament). Elle concerne en particulier des agents favorisant l'entrée pour l'administration de protéines, de polypeptides et d'analogues; des acides nucléiques et analogues; des petites molécules (souvent désignées médicaments comprenant des agents antimicrobiens) ayant des applications dans la recherche ou des utilisations médicinales/thérapeutiques. Plus spécifiquement, l'invention concerne des polymères, des protéines, des polypeptides ou des peptides naturels biodégradables existants ou des biopolymères synthétiques décorés de biguanidine. L'invention concerne également le procédé de synthèse/modification de biomolécules avec de la biguanidine. Un autre aspect de l'invention concerne la composition et le procédé de promotion de l'entrée (administration) d'agents thérapeutiques ou prophylactiques ou d'agents d'imagerie ou d'agents utilisés dans la recherche ou la thérapie. Le procédé de promotion de l'entrée d'un agent (agent introduit) dans une cellule eucaryote ou procaryote, le procédé comprenant l'étape consistant à exposer la cellule à l'agent introduit en présence d'un agent favorisant l'entrée, l'agent favorisant l'entrée comprenant un (glucide ou protéine, polypeptide ou peptide ou polyamine) naturel,linéaire et/ou ramifié ou dendrimère, naturel, un polymère synthétique ou semi-synthétique (polymères portant une amine) ayant des fractions biguanidine substituées (0,01 à 100 %).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201641005523 | 2016-02-17 | ||
IN201641005523 | 2016-02-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2017141204A2 WO2017141204A2 (fr) | 2017-08-24 |
WO2017141204A3 true WO2017141204A3 (fr) | 2017-09-28 |
Family
ID=59624833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2017/050909 WO2017141204A2 (fr) | 2016-02-17 | 2017-02-17 | Biopolymères greffés/modifiés au biguanide en tant que véhicules d'administration de médicament |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2017141204A2 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3873541A4 (fr) * | 2018-10-30 | 2022-08-31 | Ohio State Innovation Foundation | Nanoparticules activées par ph |
KR102371859B1 (ko) * | 2020-06-12 | 2022-03-07 | 연세대학교 산학협력단 | 화학적 교환에 의한 포화 전이 자기 공명 이미징용 조영제 및 이를 이용하는 화학적 교환에 의한 포화 전이 자기 공명 이미징 방법 |
CN113930454A (zh) * | 2021-11-26 | 2022-01-14 | 南通大学 | 壳聚糖-聚二甲双胍在作为基因转染试剂方面的应用 |
CN114478834B (zh) * | 2022-02-28 | 2023-08-08 | 江南大学 | 一种胍基透明质酸抗菌聚合物及其制备方法和应用 |
CN114561046B (zh) * | 2022-02-28 | 2023-10-27 | 江南大学 | 一种胍基透明质酸型抗菌水凝胶及其制备方法和应用 |
WO2023209728A1 (fr) * | 2022-04-24 | 2023-11-02 | Peptomer Therapeutics Private Limited | Peptidomimétiques cationiques de synthèse, leurs dérivés et leur préparation conjointement à des compositions pour diverses applications médicales |
CN116637173B (zh) * | 2023-05-11 | 2024-03-22 | 南京医科大学附属口腔医院 | 一种多胍抗菌肽口腔微针 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013054123A1 (fr) * | 2011-10-11 | 2013-04-18 | The Royal Veterinary College | Procédés |
-
2017
- 2017-02-17 WO PCT/IB2017/050909 patent/WO2017141204A2/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013054123A1 (fr) * | 2011-10-11 | 2013-04-18 | The Royal Veterinary College | Procédés |
Also Published As
Publication number | Publication date |
---|---|
WO2017141204A2 (fr) | 2017-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017141204A3 (fr) | Biopolymères greffés/modifiés au biguanide en tant que véhicules d'administration de médicament | |
Zhang et al. | Dynamic covalent polymers for biomedical applications | |
Raymond et al. | Low-molecular-weight supramolecular hydrogels for sustained and localized in vivo drug delivery | |
Michels et al. | Acid-mediated prevention of aspartimide formation in solid phase peptide synthesis | |
Nowak et al. | Unusual salt stability in highly charged diblock co-polypeptide hydrogels | |
Jeong et al. | Sprayable adhesive nanotherapeutics: mussel-protein-based nanoparticles for highly efficient locoregional cancer therapy | |
MX2015011393A (es) | Poli(beta-amino esteres) modificados para suministro de farmaco. | |
Xie et al. | Calcium-ion-triggered co-assembly of peptide and polysaccharide into a hybrid hydrogel for drug delivery | |
McLellan et al. | Keratin-based biofilms, hydrogels, and biofibers | |
WO2016172681A8 (fr) | Polymères à base d'eau aptes à la chimie clic et polymères à base d'eau réticulés par chimie clic | |
ATE312628T1 (de) | Kontrolliertes abbaubares polymer-biomolekül oder wirkstoffträger und verfahren zur synthese dieses trägers | |
Tian et al. | Natural electroactive hydrogel from soy protein isolation | |
BR112015023168A8 (pt) | composição de dicetopiperazina cristalina, métodos de produção de partículas de dicetopiiperazina,de produção de uma composição e de tratamento e uso de uma composição de dicetopiperazina cristalina | |
FR2885130B1 (fr) | Procede de preparation de polylysines dendrimeres greffes | |
EP2567971A3 (fr) | Vaccins de peptides avec Seq Id 80, 100 or 101 pour cancers exprimant des antigènes associés aux tumeurs | |
MX2009011813A (es) | Acidos poliglutamicos funcionalizados con grupos cationicos y grupos hidrofobicos y aplicaciones de los mismos, en particular aplicaciones terapeuticas de los mismos. | |
Schneider et al. | Layer-by-layer films from hyaluronan and amine-modified hyaluronan | |
Yishay‐Safranchik et al. | Controlled release of doxorubicin and Smac‐derived pro‐apoptotic peptide from self‐assembled KLD‐based peptide hydrogels | |
Han et al. | Recent advances of poly (ester amide) s-based biomaterials | |
DE602006008278D1 (de) | Pharmazeutische zusammensetzung | |
BR112012013139A2 (pt) | oligopeptídeos imp-3 e vacinas incluindo os mesmos | |
WO2016081616A3 (fr) | Formulations de timbre transdermique pour l'administration de médicaments hydrosolubles, de peptides, de protéines et d'oligosaccharides | |
Sun et al. | Self-sorting microscale compartmentalized block copolypeptide hydrogels | |
Chen et al. | High‐performance multi‐dynamic bond cross‐linked hydrogel with spatiotemporal siRNA delivery for gene–cell combination therapy of intervertebral disc degeneration | |
Erfani et al. | Biodegradable zwitterionic poly (carboxybetaine) microgel for sustained delivery of antibodies with extended stability and preserved function |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17752778 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17752778 Country of ref document: EP Kind code of ref document: A2 |